Analyst Price Target is $7.75
▲ +202.73% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Galera Therapeutics in the last 3 months. The average price target is $7.75, with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 202.73% upside from the last price of $2.56.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Galera Therapeutics. This Buy consensus rating has held steady for over two years.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.